Boostrix TM

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaInfections, PapillomavirusTetanus

Phase 3

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

CompletedNCT00369824

GlaxoSmithKlineInfections, Papillomavirus

Start: 2006-09-26End: 2008-02-13Updated: 2018-07-20

Phase 4

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

CompletedNCT00610168

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2008-01-01End: 2008-04-30Updated: 2018-06-06

Related Papers

Results disclosure of papilloma vaccine studies in humans completed before January 1st, 2011.

Figshare2014-01-01

Results disclosure of papilloma vaccine studies in humans co.

Figshare2014-01-01

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.

2011-12-0123 citations

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.

2010-09-0169 citations